0
Abstract: Slide Presentations |

LIPID PEROXIDATION AND GLUTATHIONE PEROXIDASE ACTIVITY IN PATIENTS WITH COPD: RELATIONSHIP TO DISEASE SEVERITY FREE TO VIEW

Ruzena J. Tkacova, MD*; Darina Petrasova, PhD; Zuzana Kluchova, MD; Pavol Joppa, MD; Roman Klimcik, MD; Zuzana Dorkova, MD
Author and Funding Information

Dept. Respirology and TB, L. Pasteur Teaching Hospital, Kosice, Slovak Republic



Chest. 2005;128(4_MeetingAbstracts):131S. doi:10.1378/chest.128.4_MeetingAbstracts.131S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  An oxidant/antioxidant imbalance is thought to play an important role in the pathogenesis of chronic obstructive pulmonary disease (COPD). We hypothesized that antioxidant capacity reflected by erythrocyte glutathione peroxidase (GPx) activity will be lower, and serum levels of the lipid peroxidation product malondialdehyde (MDA) will be higher in patients with mild compared to those with severe COPD.

METHODS:  Erythrocyte GPx activity and serum levels of MDA were measured in 103 consecutive patients with stable COPD. Pulmonary function tests were assessed using bodyplethysmography. Differences between the groups were assessed by one-way ANOVA.

RESULTS:  Moderate COPD (FEV1 50-80%) was present in 31, severe (FEV1 30-50%) in 51, and very severe COPD (FEV1 < 30%) in 21 patients. Both, erythrocyte GPx activity and serum MDA levels differed significantly between the moderate, severe, and very severe COPD groups (GPx: 47.7±2.9 versus 45.2±1.8, and 37.4±2.3 u/gHb, respectively, p<0.05; MDA: 2.1±0.9 versus 2.3±0.1, and 2.5±0.1 nmol/ml, respectively, p<0.05).

CONCLUSION:  Findings of the present study suggest that antioxidant capacity reflected by erythrocyte GPx activity and serum levels of the lipid peroxidation product MDA are linked to the severity of COPD. The lowest erythrocyte GPx activity and the highest serum MDA levels were seen in patients with very severe COPD.

CLINICAL IMPLICATIONS:  In patients with stable COPD, erythrocyte GPx activity and serum MDA levels may serve as additional markers of disease severity.

DISCLOSURE:  Ruzena Tkacova, None.

Monday, October 31, 2005

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543